Urology Center of Englewood
Latest Clinical News

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer (06-3-2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor... Continue Reading

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia (05-20-2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer (05-7-2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma (04-16-2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy,... Continue Reading

Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer (03-14-2019)

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT... Continue Reading

Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer (02-11-2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial... Continue Reading

Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer (12-31-2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In... Continue Reading

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07-17-2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (06-6-2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (05-4-2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (05-1-2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (04-3-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading

Next Page »